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Introduction
Squamous cell carcinoma of the buccal mucosa
(BMSCC) is the most common form of oral cancer in
South Asia, including India and Taiwan.1–7 BMSCC is
a rare clinical entity, accounting for approximately 10%
of all oral cancers in the United States and Western
Europe.8 BMSCC accounts for 26.5–37.4% of all intra-
oral cancers in Taiwan and buccal mucosa seems to be
the site at greatest risk of contracting malignancy in
betel quid chewers.3,7,9 Tobacco and alcohol use are
considered the major risk factors for buccal carcinoma
in the United States. Betel quid chewing is the main
risk factor for buccal cancer in Taiwan.10–13 The high
incidence of carcinoma of the buccal mucosa in Taiwan
is due to habitual betel quid chewing, which exposes
the buccal mucosa to high doses of carcinogens.14
In 2002, oral carcinoma was the 4th in cancer inci-
dence of males and the 5th leading cause of cancer
death of males in Taiwan.9 BMSCC tends to act more
aggressively than those originating in other subsites 
in the oral cavity because limited anatomic barriers
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within the buccal space provide essentially no resistance
to tumor spread.15 Therefore, it presents lower 3- and
5-year disease-specific survival rates of 62–91% and
37–76%, respectively.2,4–6,16–22 Locoregional recurrence
after surgery or even after combined surgery and
radiotherapy (RT) is the main cause of death in these
patients. BMSCC is aggressive and associated with a
poor prognosis of the high incidence of locoregional
recurrence rates of 26–80% reported in the litera-
ture.2,4,5,17–22 Available data suggest that recurrent
disease is most often locoregional, with distant metas-
tases affecting a relatively small percentage of 0–23%
of patients.2,4–6,16,18,20
Traditionally, treatment for stage I and II lesions
has been either surgery or radiation therapy as a single
modality.1 Surgical excision combined with postoper-
ative RT has been recommended for advanced-stage
tumors.5,23,24
Since there are few reports in the literature analyz-
ing the clinicopathologic aspects of the disease and
surgical treatment results of current therapy, the aim
of this study was to evaluate the prognostic factors for
survival rate and compare them with data reported in
the literature. This study represents the largest series
of previously untreated patients with BMSCC who
received curative surgeries with or without postopera-
tive RT in Southern Taiwan, where the habit of betel
quid chewing is prevalent.3,13
Methods
We reviewed the charts of 172 patients histopatho-
logically diagnosed with primary BMSCC at Kaohsiung
Veterans General Hospital between November 1990
and May 2005. Of the 172 patients, 22 were excluded:
20 patients with advanced tumors who received no
treatment or palliative treatment, and 2 patients who
had received preoperative RT. The remaining 150 pa-
tients had undergone wide excisions for buccal cancer.
If the tumor was near or had invaded the mandible
and/or maxilla, marginal or segmental mandibulectomy
and/or partial or hemimaxillectomy was performed
for adequate margins. When treating clinically negative
neck lymph nodes, neck dissection was not performed
except for intensive follow-up. In addition, modified
radical neck dissection was used when there were clin-
ically positive neck lymph nodes, unless lymph nodes
were involved in the posterior triangle of the neck
and/or the spinal accessory nerve, in which case radical
neck dissection was performed.
Tumors were staged retrospectively according to
the TNM staging system as proposed by the 2002
American Joint Committee on Cancer (AJCC).25 Of
150 patients, 66 patients (43.7%) were alive at the time
of last follow-up diagnosis. The histologic diagnosis
and report of well, moderately, or poorly differenti-
ated SCC were graded according to World Health
Organization guidelines. Surgical margin status was
determined on final histopathologic evaluation.
All patients had undergone surgeries, and 56 (37.3%)
among them had received postoperative RT. It should
be noted that RT was not given preoperatively to any
of these patients. Postoperative RT was performed 
on patients with pathologic T4 tumors, multiple posi-
tive neck lymph nodes, positive surgical margins, and
extracapsular spread (ECS). Irradiation was started 
as soon as feasible after surgery, usually within 3–8
weeks. The prescribed dose was 1.8–2.0Gy per fraction
per day, given 5 days a week. Radiation dosage ranged
from 50 to 66 Gy and was delivered in daily fractions
over 6–7 weeks. In addition, preoperative or postop-
erative chemotherapy was not used, except for palliative
treatment.
The survival time was measured from the time of
histologic diagnosis in all 150 patients who had under-
gone surgeries. The period of follow-up was calculated
as the duration between the date of initial diagnosis
to the date of death or last follow-up when alive. For
disease-specific survival, patients dying from inter-
current disease were censored at the time of death.
Survival curves were calculated by the Kaplan–Meier
product-limit method. The prognostic significance of
14 clinicopathologic factors on survival in the multi-
variate analysis was assessed using Cox’s regression
model with forward selection. SPSS version 10.0 (SPSS
Inc., Chicago, IL, USA) was used for the statistical
analysis. A p value < 0.05 was considered to be sig-
nificant. In addition, p values were for a 2-sided
hypothesis.
Results
A total of 150 patients with a diagnosis of BMSCC
met the inclusion criteria for this study. The patients
were not evenly distributed by gender (148 males, 
2 females). The overall male-to-female ratio was 74:1 in
this study. At the time of diagnosis, the mean age was
53.5 years (range, 24–85 years). The mean age of male
patients was 53.2 years (range, 24–77 years). The preva-
lence rate of habitual betel quid chewing documented
in charts among 113 patients was 75%.
The distribution according to the AJCC staging
system was: 50 (33.3%) patients with pathologic stage
I, 37 (24.7%) with stage II, 18 (12.0%) with stage III,
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and 45 (30%) with stage IV disease. The histopathol-
ogy of tumor differentiation showed that most patients
(n = 93, 62%) had moderately differentiated SCC. In
addition, 50 cases (33%) showed well-differentiated
tumor, and 7 cases (5%) had poorly differentiated SCC.
The median overall survival rate was 136.9 months
(range, 1.5–157.0 months). The 1-year, 3-year, 5-year,
10-year, and 12-year overall survival rates for all patients
were 88%, 70%, 64%, 50%, and 44%, respectively. The
1-year, 3-year, 5-year, 10-year, and 12-year disease-
specific survival rates for all patients were 89%, 72%, 69%,
59%, and 51%, respectively. There were no perioperative
deaths. Death occurred in 84 patients during follow-up.
The Kaplan–Meier overall and disease-specific survival
curves are shown in Figure 1. The 5-year survival rates
for patients with N0 and N+ neck disease were 78%
and 41%, respectively (p < 0.001). In addition, distant
metastases occurred in 14 patients (9.3%) during the
follow-up period, 11 (78.6%) of whom also showed
locoregional recurrence. Distant metastases were found
in the lung (8/14), T-spine (3/14), liver (2/14) and
brain (1/14).
The median time between initial treatment and
locoregional recurrence was 41.1 months (range,
1.5–119.7 months). Locoregional recurrence developed
in 80 patients (53.3%) during follow-up. Among them,
50 (33.3%) had disease recurrences only at the primary
sites, 16 (10.7%) had recurrences only in the ipsilateral
neck, and 14 (9.3%) patients had simultaneous primary
and neck recurrences during follow-up. Locoregional
failure was one of the main causes of subsequent death.
In the stratification analysis, we found that the 5-year
disease-specific survival rate for patients with locore-
gional recurrent disease was 58%. However, by using
the log-rank test, the disease-specific survival rate of
those with no evidence of locoregional recurrence was
found to be 84% (p < 0.001). In addition, 47 (58.8%)
out of 80 patients with recurrences were suitable for sal-
vage surgeries with wide excisions or neck dissections.
The incidence rate of second primary cancer was 19%
(28 patients), and all of them were SCCs involving the
upper aerodigestive tract.
Univariate analysis of the prognostic factors for
disease-specific survival is outlined in Table 1. The
disease-specific survival curves according to gender, age
group, betel quid chewing, second primary cancer, buc-
cinator muscle invasion, and surgical margin demon-
strated no statistical differences by univariate analysis.
However, the disease-specific survival curves were signi-
ficantly correlated with pathologic stage, T-stage, N-
stage, treatment modality, histologic grade, mandibular
bone invasion, perineural invasion, and vascular invasion
in univariate analysis. The Kaplan–Meier disease-specific
survival curves for pathologic stage and histologic grade
are shown in Figures 2 and 3, respectively.
The Cox regression model was constructed with a
forward selection in which significant variables, from
14 clinicopathologic factors, were added 1 at a time to
assess their effect on the fit of the model. Finally, only
the statistically significant prognostic factors, including
pathologic stage and histologic grade, were included
in the model (Table 2). Each of these prognostic factors
was considered to have an independent association
with death. Patients with stage IV tumors had a 6.56
greater risk of death when compared with those having
stage I tumors. In addition, patients with moderately or
poorly differentiated cancer had a 2.35 higher risk of
death compared with patients with well-differentiated
cancer.
Discussion
BMSCC is rare in the United States and Western
Europe, where the major risk factors of oral cancers
are thought to be alcohol drinking and tobacco smok-
ing. In contrast, BMSCC occurs frequently in India,
Southeast Asia (including Taiwan) and numerous other
countries where chewing of betel quid is popular.10–12
Of the 150 patients in this study, only 1.3% 
were females. The selection effect of sex in our 
hospital cannot be ruled out. This rate was slightly
less than the 4–7% in Taiwanese,2,5,6 but was signifi-
cantly less than the 13–86% in Indians, or 38–87% in
Americans.4,16,18–22,26,27 The discrepancy in sex ratio
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Figure 1. The 5-year disease-specific survival in a recent cohort of
150 patients with squamous cell carcinoma of the buccal mucosa
treated at Kaohsiung Veterans General Hospital. Survival rate 
is demonstrated with the use of the Kaplan–Meier product limit
method.
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Table 1. Univariate analysis of clinicopathologic prognostic factors on disease-specific survival in BMSCC patients
Survival (n = 150)
5-year disease-specific survival rate p* RR (95% CI) p†
Gender
Female (2) – 0.531 1.00
Male (148) 0.69 0.05 (0.00–70285.3) 0.677
Age (yr)
≤ 40 (18) 0.66 0.754 1.00
41–50 (45) 0.66 1.12 (0.41–3.10) 0.822
51–60 (43) 0.69 1.09 (0.39–3.07) 0.871
> 60 (44) 0.75 0.83 (0.26–2.18) 0.600
Betel quid chewing
No (37) 0.80 0.056 1.00
Yes (113) 0.66 2.26 (0.95–5.35) 0.064
Pathologic stage
I (50) 0.90 < 0.001 1.00
II (37) 0.77 2.61 (0.95–7.21) 0.063
III (18) 0.52 4.62 (1.59–13.38) 0.005
IV (45) 0.47 7.41 (2.91–18.87) < 0.001
T-stage
T1 (54) 0.89 < 0.001 1.00
T2 (48) 0.68 3.20 (1.31–7.82) 0.011
T3 (8) 0.31 8.98 (2.78–29.02) < 0.001
T4 (40) 0.52 5.97 (2.40–14.85) < 0.001
N-stage
N0 (115) 0.78 < 0.001 1.00
N1 (21) 0.61 1.77 (0.82–3.82) 0.147
N2 (14) 0.00 14.83 (6.33–34.71) < 0.001
Secondary primary
No (122) 0.70 0.902 1.00
Yes (28) 0.68 1.05 (0.50–2.18) 0.902
Treatment modality
Surgery alone (94) 0.78 0.005 1.00
S + RT (56) 0.57 2.28 (1.25–4.14) 0.007
Histologic grading of differentiation
Well (50) 0.87 < 0.001 1.00
Moderate (93) 0.65 2.51 (1.19–5.31) 0.016
Poor (7) 0.00 7.02 (2.30–21.39) < 0.001
Invasion of buccinator muscle
No (93) 0.68 0.620 1.00
Yes (57) 0.71 0.85 (0.46–1.59) 0.616
Mandibular invasion
No (134) 0.73 < 0.001 1.00
Yes (16) 0.43 3.26 (1.56–6.84) 0.002
Perineural invasion
No (135) 0.72 0.006 1.00
Yes (15) 0.44 2.96 (1.30–6.76) 0.010
Vascular invasion
No (139) 0.72 < 0.001 1.00
Yes (11) 0.00 4.82 (1.98–11.72) 0.001
Surgical margins
Negative (120) 0.74 0.054 1.00
Positive (30) 0.52 1.88 (0.98–3.62) 0.058
*p estimated by log-rank test; †p estimated by Cox’s regression. BMSCC= squamous cell carcinoma of the buccal mucosa; RR= relative risk of death; CI= confidence
interval; S = surgery; RT = radiotherapy.
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reflects the fact that the prevalence of betel quid
chewing is much higher among males than females in
Taiwan (20.9% vs. 1.2%).28
The 3-year disease-specific survival rate (72%) in this
study was lower than those in the other studies (range,
78–91%).4,6 Yet, the 5-year disease-specific survival rate
(69%) was moderate as compared with those in the other
studies (range, 37–76%).5,6,16–22 The different clini-
copathologic characteristics of patients and treatment
modalities received by patients may explain the vari-
ous survival rates between studies. For example, there
were 2 studies with obviously higher survival rates
than ours. One is the study of Iyer et al,4 with a 3-year
disease-specific survival rate of 91% for 147 patients
with early-stage BMSCC who underwent peroral wide
excisions. The other is the study of Liao et al,6 with 
a 5-year disease-specific survival rate of 76% for 232
patients treated with radical surgeries with or without
neck dissection. Compared to our study, more patients
with early-stage disease in Iyer et al’s4 study and those
in Liao et al’s6 underwent extra aggressive radical sur-
gery and neck lymph node dissection, which explains
their higher survival rates. In addition, there was a
recent study from Taiwan by Lin et al5 with relatively
lower survival rates than ours. That study showed that
the 5-year disease-specific survival rate was only 37%
for 121 patients who received different treatment
modalities (surgery alone, RT alone, and surgery with
postoperative RT). The most likely reason was that
more patients in their study were in the advanced
stages than in our study (63.6% vs. 42%). Additionally,
1-third of their patients (30%) only received RT alone,
which had a very poor survival in either the early- or
the advanced-stage disease.1,5 Furthermore, there were
2 studies with survival rates comparable to ours. One
is the study of Diaz et al,21 which reported a 5-year
disease-specific survival rate of 63% for 119 patients
treated at a single institution. The other is a study by
Fang et al2 from Southern Taiwan, which found that
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Figure 2. Effect of pathologic stage on survival. Survival curves
were calculated based on all deaths by using the Kaplan–Meier
life table method.
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Figure 3. Effect of histologic grading of differentiation on survival
rate.
Table 2. Cox’s regression of prognostic factors on survival for squamous cell carcinoma of the buccal mucosa
Factor (no. of patients) ARR (95% CI) p
Pathologic stage
I (50) 1.0
II (37) 2.59 (0.94–7.15) 0.066
III (18) 4.76 (1.63–13.85) 0.004
IV (45) 6.56 (2.55–16.86) < 0.001
Histology
Well (50) 1.0
Moderate + poor (100) 2.35 (1.11–4.96) 0.026
Cox’s regression analysis for relative risk of death after adjusting for variables in each other. ARR = adjusted relative risk of death; CI = confidence interval.
the 3-year disease-specific survival rate for 57 patients
treated by surgery and postoperative RT was 62% (60%
in our 56 patients).
Multivariate analysis permitted stratification of all
150 patients into different death risk categories based
on pathologic staging and histologic grading. Diaz 
et al21 reported the MD Anderson experience for 119
patients with BMSCC treated with surgery alone (84
patients) or surgery combined with adjuvant radia-
tion therapy (35 patients) between 1974 and 1993.
The 5-year disease-specific survival rate was 63%; and
by stages, the disease-specific survival rates were: 78%
in stage I, 66% in stage II, 62% in stage III, and 50%
in stage IV (p = 0.030). In our series, for patients with
stages I, II, III and IV disease, the 5-year disease-
specific survival rates were 90%, 77%, 52% and 47%,
respectively (p < 0.001). This indicated that the patients
who were treated in their early stages had better prog-
noses and survival rates.1,4,6,21
The presence of regional metastasis was an impor-
tant factor for the prognosis.6,16,21 Diaz et al21 demon-
strated that the 5-year survival rate for patients with
N0 and N+ neck were 70% and 49%, respectively
(p = 0.0116). Our study result was comparable with
the above results (78% vs. 41%, p < 0.001).
The prognostic value of histologic grading has been
controversial, with conflicting evidence in the litera-
ture.29,30 Patients with moderately/poorly differenti-
ated cancer in our study had a poor survival rate. Liao
et al6 found that poor differentiation of cancer (HR,
1.050; 95% CI, 1.016–1.084; p = 0.034) was a signifi-
cant factor for disease-specific survival in multivariate
analysis. In our series, the mortality rate in patients
with moderately/poorly differentiated cancer was 2.35
times higher compared with that in patients with well-
differentiated cancer in multivariate analysis. A probable
reason was that the moderately/poorly differentiated
cancers tended to present more often with N+ disease
than well-differentiated tumors (p = 0.02). Iyer et al4
suggested that these patients with poorly differentiated
carcinoma should be treated more aggressively (i.e.
selective neck dissection and postoperative RT).
The 53.3% rate of locoregional recurrence encoun-
tered in this study is just slightly lower than the range
of 56–80% reported by others.5,18,19 The recurrence
rate of our study was higher than the range of 26–47%
reported in the literature.2,4,17,20–22,27 Many previous
surveys demonstrated that local recurrence rates are
quite high, ranging between 45% and 80%.17–19 The
rate of local recurrence is relatively high due to the lack
of anatomic barriers to spread in the buccal space.15
Failure of locoregional control negatively affects sur-
vival in patients with BMSCC. Sieczka et al19 found
that the 5-year survival rate was 100% for those with no
evidence of locoregional recurrence and declined to
50% for patients with recurrent disease (p = 0.001).
Our findings were comparable with the above results,
84% vs. 58% (p < 0.001).
Our study supports the findings of others that oral
cavity carcinomas are notorious for development of
second primary cancer.31 There is a 14–37% incidence
of second primary cancers; these mainly involve the
upper aerodigestive tract.4,8,18,20,26 Our study found
that the incidence rate of second primary cancer was
19% (28 patients), which was comparable with reports
in the literature. In addition, they were all SCCs in-
volving the upper aerodigestive tract. It was notewor-
thy that the majority of these tumors were SCC and
involved the upper aerodigestive tract, suggesting a
mucosa field change.31 For example, Chhetri et al20 re-
ported a 37% incidence of second primary neoplasms,
90% of which were SCC involving the upper aerodi-
gestive tract.
In the literature, the incidence of systemic dis-
semination for BMSCC ranges from 0% to
23%.2,4–6,16,18,20,21,26 In our study, 14 patients (9%)
developed distant metastases, and lungs were the most
common sites. Fang et al2 found a 7% rate of distant
metastasis for 57 patients with BMSCC treated by sur-
gery and postoperative RT. Distant metastases occurred
in 19 patients (15.7%), 14 of whom also had locore-
gional recurrence in the study by Lin et al.5 Liao et al6
reported that the 5-year distant metastasis rate was
14%; lungs and bones were the most frequent sites for
distant metastases.32
In conclusion, the strong influence of disease stage
on prognosis emphasizes the importance of early diag-
nosis of BMSCC and aggressive treatment for patients
with poorly/moderately differentiated cancer.
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